Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 20, 2016

Sanofi Genzyme begins Phase III COMET clinical trial of neoGAA to treat Pompe disease in UK

Sanofi Genzyme has begun enrolment and dosed the first UK patient for its pivotal Phase III COMET clinical trial of neoGAA to treat Pompe disease.

Sanofi Genzyme has begun enrolment and dosed the first UK patient for its pivotal Phase III COMET clinical trial of neoGAA to treat Pompe disease.

NeoGAA is an investigational, second-generation, alglucosidase alfa enzyme replacement therapy designed for enhanced receptor targeting and enzyme uptake with greater affinity for the M6P receptors on muscle cells.

It is aimed at improving glycogen clearance and improving on the clinical efficacy achieved with alglucosidase alfa.

Pompe disease is a progressive, debilitating and often fatal neuromuscular disease triggered by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA).

Newcastle Hospitals NHS Foundation Trust and Newcastle University John Walton Muscular Dystrophy Research Centre principal investigator Professor Volker Straub said: "Pompe disease is a serious, progressive and debilitating disorder.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
"Dosing the first patient in the UK is an exciting and important milestone in our quest to advance treatment options for patients with this disease."

"Dosing the first patient in the UK is an exciting and important milestone in our quest to advance treatment options for patients with this disease."

The Phase III multi-centre, multi-national, double-blinded COMET study is being conducted to compare the safety and efficacy of repeated bi-weekly infusions of neoGAA and alglucosidase alfa in 96 treatment-naïve patients with late-onset Pompe disease.

The study is primarily focused on determining the effect of neoGAA on respiratory muscle strength as measured by percent predicted forced vital capacity in the upright position.

It will also assess functional endurance measured by the six minute walk test, muscle strength, motor function, health-related quality of life, and patient reported outcomes.


Image: Muscle biopsy reveals large vacuoles in a case of Pompe disease. Photo: courtesy of Jensflorian.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU